文献速递银屑病与炎症性皮肤病

以色列银屑病患者生物制剂药物留存率研究

Biologic drug survival in Israeli psoriasis patients.
PubMed 文献 · J Am Acad Dermatol · 2016-12-28

基于Clalit健康服务数据库,对907例接受1575次生物制剂治疗的重度银屑病患者进行生存分析。乌司奴单抗的留存率显著高于肿瘤坏死因子抑制剂;生物制剂初治和联用甲氨蝶呤为正向预测因素,女性性别和既往系统治疗时长为负向预测因素。

要点

  • 乌司奴单抗留存率显著优于TNF抑制剂
  • 生物制剂初治和联用甲氨蝶呤预测更长的药物留存
  • 女性性别和既往系统治疗时间长降低药物留存

核心结论

  • 在重度银屑病患者中,乌司奴单抗相比其他被研究的生物制剂具有更好的留存率,多数患者将其作为三线治疗使用。

研究设计与样本

  • 对Clalit健康服务数据库中接受阿达木单抗、英夫利西单抗、依那西普和乌司奴单抗治疗的重度银屑病患者进行生存分析,共907例患者、1575次生物制剂治疗。
  • 多因素分析校正了人口学变量、代谢综合征及其组分、银屑病关节炎、生物制剂初治状态、联用甲氨蝶呤/阿维A/环孢素及既往标准系统治疗暴露。

主要发现

  • 乌司奴单抗的留存率显著高于肿瘤坏死因子抑制剂。
  • 生物制剂初治和联用甲氨蝶呤是药物留存的正向预测因素。
  • 女性性别和既往系统治疗时长为药物留存的负向预测因素。

临床怎么用

  • 在重度银屑病生物制剂选择中,可考虑乌司奴单抗具有较好的药物留存。
  • 生物制剂初治患者及联用甲氨蝶呤可能有助于延长药物留存。
  • 女性患者及既往系统治疗时间较长者需关注药物留存可能较短。

局限性

  • Clalit健康服务数据库无法获取疾病严重程度或病程数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Drug survival is defined as the time period of treatment with a certain drug until its cessation. The role of previous exposure to traditional systemic treatments in biologic survival is still unknown. OBJECTIVE: To investigate the drug survival rates of biologic treatments in patients with psoriasis and to identify predictor factors. METHODS: Survival analysis was performed on patients with severe psoriasis who received adalimumab, infliximab, etanercept, and ustekinumab for treatment of psoriasis, drawn from the Clalit Health Services database. Multivariate analysis was performed adjusting for demographic variables; metabolic syndrome and its components; psoriatic arthritis; biologic naivety; coadministration of methotrexate, acitretin, or cyclosporine; and previous standard systemic treatment exposure. RESULTS: Among 907 patients treated with 1575 biologic treatments, ustekinumab had a significantly higher survival rate than tumor necrosis factor inhibitors. Biologic naivety and concomitant methotrexate intake were positive predictors for drug survival, whereas the female sex and the duration of previous systemic treatments were negative predictors. LIMITATIONS: Data regarding disease severity or duration could not be drawn from the Clalit Health Services database. CONCLUSION: Ustekinumab had better retention rates in comparison with other investigated biologics in patients with severe psoriasis, most of whom used it as a third line therapy.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Shalom G, Cohen AD, Ziv M, et al. Biologic drug survival in Israeli psoriasis patients. J Am Acad Dermatol. 2016. PMID: 28038888. doi:10.1016/j.jaad.2016.10.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。